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ABSTRACT
Objectives: We performed a systematic review and
meta-analysis of studies on high-sensitivity C-reactive
protein (hs-CRP) assays to see whether these tests are
predictive of atrial fibrillation (AF) recurrence after
cardioversion.
Design: Systematic review and meta-analysis.
Data sources: PubMed, EMBASE and Cochrane
databases as well as a hand search of the reference lists
in the retrieved articles from inception to December
2013.
Study eligibility criteria: This review selected
observational studies in which the measurements of
serum CRP were used to predict AF recurrence. An hs-
CRP assay was defined as any CRP test capable of
measuring serum CRP to below 0.6 mg/dL.
Primary and secondary outcome measures:We
summarised test performance characteristics with the
use of forest plots, hierarchical summary receiver
operating characteristic curves and bivariate random
effects models. Meta-regression analysis was performed
to explore the source of heterogeneity.
Results:We included nine qualifying studies comprising
a total of 347 patients with AF recurrence and 335
controls. A CRP level higher than the optimal cut-off
point was an independent predictor of AF recurrence after
cardioversion (summary adjusted OR: 3.33; 95% CI 2.10
to 5.28). The estimated pooled sensitivity and specificity
for hs-CRP was 71.0% (95% CI 63% to 78%) and
72.0% (61% to 81%), respectively. Most studies used
a CRP cut-off point of 1.9 mg/L to predict long-term AF
recurrence (77% sensitivity, 65% specificity), and 3 mg/L
to predict short-term AF recurrence (73% sensitivity,
71% specificity).
Conclusions: hs-CRP assays are moderately accurate in
predicting AF recurrence after successful cardioversion.
INTRODUCTION
Atrial ﬁbrillation (AF) is the most common
arrhythmia in clinical practice, although the
prevalence is highest among people of
advanced age.1 2 AF poses a signiﬁcant
economic burden, with a 66% increase in hos-
pital admissions over the past two decades. It is
estimated that the number of patients affected
by AF is likely to grow 2.5-fold by the year
2050.1–3 In addition, AF may lead to debilitat-
ing complications such as ischaemic stroke
and heart failure. Although ventricular rate
control is an acceptable treatment strategy in
many patients, some patients may remain
symptomatic despite adequate rate controls.
For this group of patients, cardioversion may
be the treatment of choice. Electrical cardio-
version can restore sinus rhythm effectively in
most patients and can act with antiarrhythmic
drugs synergistically to enhance the cardiover-
sion success rate.4 However, cardioversion is
not the deﬁnite treatment. Approximately
50% of patients undergoing cardioversion
usually present with recurrence of AF within
3–6 months of cardioversion despite ongoing
antiarrhythmic treatment.5 Left ventricular
Strengths and limitations of this study
▪ This meta-analysis finding supports that meas-
urement of C-reactive protein (CRP) levels before
cardioversion can aid in the prediction of atrial
fibrillation recurrence.
▪ We reported summary likelihood ratios as an
ancillary measure of predictive accuracy.
▪ We used a bivariate random effect model to
account for the inherent negative correlation
arising from different cut-off values used in dif-
ferent studies, and occurring between the logit
true positive rates and false positive rates.
▪ Results of sensitivity analysis did not show a sig-
nificantly different overall predictive accuracy
between long-term and short-term follow-up,
however a heterogeneity tended towards between-
study variability.
▪ Current summary estimates based on the one
cut-off point may thus have under-evaluated the
clinical usefulness of hs-CRP assays.
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dysfunction, left atrial enlargement, arrhythmia duration
and history of hypertension are major risk factors for AF
recurrence.6 However, recent studies have indicated that
inﬂammation, necrosis and ﬁbrosis play roles in the struc-
tural remodelling process of the atria, contributing to the
perpetuation or recurrence of AF.
C-reactive protein (CRP) is an acute-phase reactant
whose levels increase in response to proinﬂammatory cyto-
kines, notably interleukin-6, and other endogenous signals
of innate immunity or tissue damage. CRP has recently
been shown to be associated with cardiovascular risk and
AF recurrence. A previous meta-analysis revealed that CRP
is elevated in patients with AF.7 However, ﬁve of the six
studies included in that analysis used traditional auto-
mated immunonephelometric assays to measure CRP.
Unfortunately, those assays are insufﬁciently sensitive for
measuring the low level of inﬂammation associated with
AF. A newer enzyme immunoassay, namely high-sensitivity
CRP (hs-CRP), is capable of measuring serum CRP below
0.6 mg/dL and may further enhance the predictability of
AF recurrence.8 Since 2006, several studies evaluating the
accuracy of hs-CRP in predicting AF recurrence have been
published,9–19 warranting a systemic and quantitative
summary of current evidence on the accuracy of CRP in
predicting AF recurrence after cardioversion.
METHODS
Identification of studies
General bibliographic databases (MEDLINE and
EMBASE) were searched from inception to April 2013.
The medical subject heading (MeSH) and text words for
the term C-reactive protein were combined with the
MeSH term ‘diagnosis of atrial ﬁbrillation’. The search
was limited to human studies with no language restric-
tions. In addition to the electronic search, reference lists
in all known reviews and primary studies were checked
manually.
Selection criteria
This review focused on observational studies in which
the measurements of serum CRP were used to predict
AF recurrence. The population of interest comprised
patients with paroxysmal or persistent AF who under-
went electric cardioversion, ablation therapy or pharma-
cological cardioversion. AF recurrence was deﬁned as
AF documented by ECG at any time after the cardiover-
sion during the follow-up period. Generally, patients
were instructed to return to the clinic if the symptoms
such as palpitations, shortness of breath or chest discom-
fort developed after cardioversion. We included studies
using a cohort design or case–control design with appro-
priate controls. Two reviewers independently assessed eli-
gible articles for inclusion. Disagreements were initially
resolved by consensus and using arbitration by a third
reviewer if consensus could not be reached by the two
reviewers. We extracted data from the included studies.
Data collected include study design, participants,
country, period of recruitment, hs-CRP assay, cut-off
points, length of follow-up period and recurrence of AF.
One reviewer extracted the data and a second reviewer
independently veriﬁed the correctness of the extracted
data.
Quality assessment
We assessed the methodological quality of the selected
studies using a well validated tool for assessment of
quality of diagnostic accuracy studies (Quality
Assessment of Diagnostic Accuracy Studies, QUADAS).20
The QUADAS instrument scrutinises characteristics of
study designs, population, index tests and reference stan-
dards that may be associated with risk of bias. These fea-
tures included the spectrum of patients, whether index
tests and reference standards were evaluated and inter-
preted independently to avoid incorporation bias, and
whether all patients underwent the same reference stan-
dards to avoid differential or partial veriﬁcation bias.
Data abstraction
One reviewer independently extracted the data and a
second reviewer independently veriﬁed the data.
Extracted data comprised the following: overall study
characteristics (including the ﬁrst author, country, lan-
guage and date of publication); patient characteristics
(including age range and pre-existing AF); quantitative
data required for construction of a 2×2 table (including
number of participants, sensitivity, speciﬁcity and recur-
rence case number; see online supplementary table);
information regarding the hs-CRP assay (including
brand name of the test kit, cut-off levels and quantitative
or semi-quantitative nature of the test); and study set-
tings. In studies that reported multiple pairs of sensitivity
and speciﬁcity data, we consistently used the data with
the highest Youden index (sensitivity+speciﬁcity−1) and
performed a sensitivity analysis at a later stage.
Quantitative data synthesis
We performed a meta-analysis of diagnostic test accuracy
of CRP testing for the prediction of recurrent AF. We
calculated the pooled sensitivity and speciﬁcity, positive
and negative likelihood ratios, and the diagnostic OR of
CRP, along with the respective 95% CIs, using a bivariate
meta-analysis model.21 Likelihood ratios were then trans-
lated to post-test probability by use of Fagan’s plot. We
constructed a hierarchical summary receiver operating
characteristic curve that plots sensitivity versus speciﬁcity
and calculated the area under the curve.22 We evaluated
the degree of between-study heterogeneity by using the
I2 test.23 To explore the clinical sources of heterogeneity,
we deﬁned the potential explanatory variables a priori
and performed subgroup analysis to see if the accuracy
estimates changed signiﬁcantly across various subgroups.
The presence and the effect of publication bias were
examined using a combination of the Egger tests.24
Statistical analyses were conducted using STATA V.11.0,
notably with the user-written ‘midas’ and ‘metandi’
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programs. All statistical tests were two-sided and statistical
signiﬁcance was deﬁned as p < 0.05.
Search results and study characteristics
The ﬂow of inclusion and exclusion is summarised in
ﬁgure 1. Using our search criteria, we identiﬁed 784
studies, of which 352 were from PubMed and 432 were
from EMBASE. A total of 752 citations were excluded
based on predeﬁned criteria. No additional citations
were identiﬁed from the reference lists. A total of 32
articles were retrieved for full-text review, and 23 were
excluded due to various reasons detailed in ﬁgure 1.
A total of nine studies that evaluated the accuracy of
hs-CRP tests in predicting AF recurrence after cardiover-
sion were ﬁnally included in the meta-analysis. The nine
studies included a total of 682 patients with AF after suc-
cessful cardioversion, of which 347 (50.9%) developed
recurrence.
Characteristics of included studies
Table 1 lists the study and population characteristics of
the nine patient populations, excluding ﬁve studies
that do not have sufﬁcient data for statistical ana-
lysis.25–29 The mean age of patients in the included
studies ranged from 55.1 to 67.9 years and the mean
follow-up period ranged from 30 days to 1 year. Seven
studies included patients with persistent AF, while two
studies included patients with paroxysmal AF. Seven
studies used electric shock, one used circumferential
pulmonary vein isolation (also known as electric abla-
tion) and the other used intravenous amiodarone as
the primary method for cardioversion. A total of seven
studies provided multivariate (adjusted) ORs to evalu-
ate the independent predictive value of CRP levels.
These studies generally adjusted for potential predic-
tors of AF recurrence such as age, sex, use of antiar-
rhythmic agents, and heart structural and functional
parameters. All studies showed that CRP was a signiﬁ-
cant independent predictor of AF recurrence.
Associated adjusted ratios and adjusted variables are
summarised in table 1.
Quality assessment
Results of the quality assessment of studies of diagnos-
tic accuracy are summarised in ﬁgure 2. All studies
were prospective and enrolled consecutive outpatients
with AF after cardioversion. Three studies had a short
follow-up period (ie, ≤0.5 or 1 year). Although most of
the studies did not indicate whether physicians were
blinded to the index tests when diagnosing AF recur-
rence, the determination of AF recurrence was not
affected by the knowledge of hs-CRP test results and
risk of incorporation bias was minimal. None of the
studies reported the undetermined results or
withdrawals.
Figure 1 A simplified flow chart
to identify and to include studies.
Among 752 citations in MEDLINE
and EMBASE from inception to
December 2013, a search limited
to human studies using
‘C-reactive protein’ and the
medical subject heading (MeSH)
term ‘diagnosis of atrial fibrillation’
resulted in 32 potentially relevant
articles for further review. After
careful scrutinisation on full text,
nine articles were left for
meta-analysis.
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Table 1 Summary of the characteristics of the included studies
Author, year,
country
Mean
age
Prevalence
(N)
Follow-up
time
Cut-off
(mg/L) AF type Cardioversion
Sensitivity,
pecificity (%) Adjusted OR Adjusted variables
Wazni, 2005,
USA16
67.3 0.68 (111) 76 days 3.1 Persistent AF Electric 59, 69 2.0 (1.2 to 3.2) Age, sex, duration of AF, coronary
artery disease, hypertension, left
ventricular hypertrophy, LAD
Zarauza, 2006,
Spain19
62.7 0.43 (37) 30 days 3.0 Persistent AF Electric 81, 67 3.7 (1.3 to 10.8) Sex, age, time, size of left atrium,
history of hypertension,
pharmacological treatment
Watanabe, 2006,
Japan18
64 0.76 (84) 1 year 0.6 Persistent AF Electric 75, 90 5.3 (2.5 to 11.5) Sex, coronary artery disease,
hypertension, smoking, diabetes, AF
duration, LAD, LVEF
Loricchio, 2007,
Italy15
67 0.52 (102) 1 year 1.9 Persistent AF Electric 87, 37 5.0 (1.8 to 14.3) Age, gender, EF, LAD,
hypertension, diabetes,
pharmacological treatment
Lombardi, 2008,
Italy14
67 0.34 (53) 21 days 3.6 Persistent AF Electric 64, 83 1.6 (1.0 to 2.5) Age, LAD, LAA, LAAEV, NTproBNP
level, history of AF, AF duration,
pharmacological treatment
Henningsen,
2009, Denmark12
65 0.68 (56) 180 days 3.0 Persistent AF Electric 60, 83 7.7 (1.9 to 31.1)* NA
Rizos, 2010,
Greece17
67.9 0.64 (61) 1 year 2.3 Paroxysmal AF Pharmacologic 72, 68 6.2 (2.2 to 17.6) IL-6, age, gender, PAF history, LAD,
EF, diabetes, smoking
Liu, 2011,
China13
55.1 0.39 (44) 1 year 1.9 Paroxysmal AF Electric
ablation
79, 70 5.1 (2.1 to 12.1) Age, gender, type of AF, duration of
AF, LAD, LVEF, plasma hs-CRP
concentration
Barassi, 2012,
Italy10
66.9 0.33 (57) 21 days 3.0 Persistent AF Electric 74, 84 14.9 (3.9 to 57.2)* NA
*Crude effect estimate.
AF, atrial fibrillation; BNP, b-type natriuretic peptide; EF, ejection fraction; hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; LAA, left atrial appendage; LAAEF, left atrial appendage
ejection fraction; LAD, left anterior descending coronary artery; LVEF, left ventricular ejection fraction; NA, not applicable; NTproBNP, N-terminal prohormone of brain natriuretic peptide; PAF,
paroxysmal atrial fibrillation.
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Diagnostic accuracy indices
Sensitivity, specificity and diagnostic OR
The estimated sensitivity and speciﬁcity were relatively
consistent across studies (I2=14.6%). Table 2 shows the
results of individual and combined sensitivity estimates
for the tests. The estimated pooled sensitivity and speciﬁ-
city for hs-CRP were 71.0% (95% CI 63% to 78%) and
72.0% (61% to 81%), respectively. The pooled preva-
lence of AF recurrence was 54% herein, and we used it
as the pre-test probability. With a pooled positive likeli-
hood ratio of 2.57 and a negative likelihood ratio of 0.4,
the post-test probability for AF recurrence for a positive
hs-CRP test result was 72% and a post-test probability for
a negative hs-CRP test result was 29%. The area under
the receiver operating curve showed an acceptable
overall measurement of discrimination (0.77, ﬁgure 3).
Figure 4 shows the forest plot of the ORs.
Subgroup analysis and meta-regression
In view of the potential inﬂuence of spectrum variability,
we considered the duration of follow-up, mode of cardi-
oversion and type of AF in the study patients to be
important. hs-CRP test results generally had higher sen-
sitivity and lower speciﬁcity in predicting long-term over
short-term AF recurrence. Excluding two studies not
using electric shock as the primary cardioversion
method did not signiﬁcantly alter the predictive accur-
acy. Similarly, focusing the study patients on persistent AF
population had similar results as compared with the main
overall analysis. Exploratory meta-regression analysis did
not ﬁnd that any pre-speciﬁed covariate signiﬁcantly
changed the effect estimate.
DISCUSSION
This meta-analysis shows that elevated CRP levels are
independently predictive of AF recurrence in patients
with persistent or paroxysmal AF who have undergone
successful cardioversion. This ﬁnding supports that
measurement of CRP levels before cardioversion can
aid in the prediction of AF recurrence. Despite the
modest pooled sensitivity and speciﬁcity, the rule-in
diagnostic value was still high, given the high recur-
rence rate of AF observed in these included studies.
A positive hs-CRP test result at baseline can predict a
73% chance of AF recurrence in the 6–12 months fol-
lowing cardioversion.
Previous studies have examined risk factors that
predict AF recurrence. Traditional clinical risk factors
for recurrence include history of multiple AF episodes,
use of diuretic treatment, higher CHADS-2 (congestive
heart failure, history of hypertension, age≥75 years, dia-
betes mellitus, and past history of stroke or transient
ischaemic attack doubled) index score, and frequent use
of amiodarone, calcium-channel blockers, class 1C drugs
and digitalis.30 31 Although each of these factors could
predict AF recurrence with some accuracy, a quantitative
combination of these predictors is not available, and the
clinical utility of these variables remains questionable.
This also suggests that a multivariate prediction model
should be developed for AF recurrence, and that
hs-CRP should be a candidate for inclusion in the
model.
During the past decade, serum biomarkers have
emerged as practical tools to help in the early identiﬁ-
cation of patients at high risk for various cardiac
events. Elevation of inﬂammatory markers is associated
with sudden cardiac death in patients with heart failure
or coronary artery disease, and onset of ventricular
arrhythmia.32–35 Of note, there is abundant evidence
that elevated serum levels of CRP are associated with
the genesis and perpetuation of AF. CRP is the most
commonly used clinical inﬂammatory biomarker. It is
mainly produced in liver and by inﬂammatory cells in
Figure 2 The quality
assessment of diagnostic
accuracy on studies. A spectrum
of features were analysed to
avoid bias using a well validated
tool, Quality Assessment of
Diagnostics Accuracy Studies
(QUADAS). Percentage for each
feature was independently
evaluated among the studies. It is
worthy of attention that none of
the studies explained the
withdrawal and reported
undetermined results, likely to
compromise the quality of
diagnostic accuracy.
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response to proinﬂammatory cytokine stimulation.
Although the pathophysiology of AF remains elusive,
there is pathophysiological evidence supporting the
role of inﬂammation in the initiation, maintenance
and perpetuation of AF.36 Clinically, AF is frequently
associated with local inﬂammatory diseases such as
myocarditis or pericarditis, and systemic inﬂammatory
status, such as postoperative state and severe sepsis.
Histologically, structural remodelling of the atria mani-
fested by loss of myocardium and increased atrial ﬁbro-
sis is a hallmark of AF.37 Inﬂammatory cell inﬁltrates
and oxidative damage have been demonstrated in atrial
biopsy specimens from AF patients.38 Activated inﬂam-
matory cells in conjunction with reactive oxygen
species, cytokines and growth factors, may ultimately
lead to matrix deposition with atrial ﬁbrosis. Recent evi-
dence also shows that the uses of immune-modulating
agents such as statins, ACE inhibitors or glucocorticoids
modulate the course of AF.39
In addition to CRP, b-type natriuretic peptide (BNP)
has been shown to be an indicator of new onset AF and
AF recurrence after successful cardioversion.34 35 40 BNP
is also produced in response to atrial pressure and
volume overload and there is evidence that BNP is
secreted by the atrium in patients with AF. A previous
meta-analysis showed that the standardised mean differ-
ence in plasma BNP level between patients with non-
recurrence and patients with recurrence was −1.35 (95%
CI −2.17 to −0.53).41 Data on sensitivity and speciﬁcity
in that study were not available. The comparative accur-
acy between BNP and hs-CRP in predicting AF recur-
rence thus requires further analysis.
There are both strengths and limitations in our study.
Considering the limitation of sensitivity and speciﬁcity
in clinical interpretation, we reported summary likeli-
hood ratios (LRs) as an ancillary measure of predictive
accuracy. The LRs indicate how much a given CRP
testing result increases or decreases the probability of
recurrence of AF. Post-test probabilities can be derived
from pre-test probabilities and LRs, which are an
important clinical parameter for major clinical decision
making. Second, we used a bivariate random effect
model to account for the inherent negative correlation
arising from different cut-off values used in different
studies, and occurring between the logit true positive
rates and false positive rate. Third, we performed sensi-
tivity analysis by restricting analysis within two broad cat-
egories of follow-up duration. Results of sensitivity
analysis did not show a signiﬁcantly different overall
predicative accuracy between long-term and short-term
prediction of AF recurrence. Nonetheless, it is note-
worthy that the sensitivity may be overestimated in our
study under the hypothesis where the inﬂammation
may be symptomatic since none of the studies provided
withdrawal and undetermined results, and the ascertain-
ment of AF was passive. This event further introduces
the differential veriﬁcation bias. Moreover, our
meta-analysis is restricted to distinguishing hs-CRP levels
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above or below 0.6 mg/dL because the authors in only
one of the studies claimed to possess such capability.
Finally, due to the lack of individual data, it is hard to
determine whether the area under the receiver
operating curve can be improved by the new assay
either on overall or on individual studies. In general,
potential sources of between-study variability included
differences in incidence of AF recurrence, different
threshold values of CRP concentration used and differ-
ent duration for follow-up. Another limitation was the
strategy we used to determine the optimal cut-off value.
Most studies determined an optimal cut-off value to
maximise both sensitivity and speciﬁcity. Although a
single cut-off value is straightforward in clinical inter-
pretation, it may make a marker neither sensitive nor
speciﬁc enough to rule out or rule in an outcome of
interest. A two cut-off value strategy, with one using a
lower cut-off value to optimise the sensitivity (rule-out
value) and the other using a higher cut-off value to
optimise the speciﬁcity (rule-in value), would make
better use of the information that a biomarker with a
continuous value could provide. Current summary esti-
mates based on the one cut-off point may thus have
under-evaluated the clinical usefulness of hs-CRP assays.
To make the best use of the biomarker information by
adopting a two cut-off point strategy or a multi-cut-off
point risk classiﬁcation strategy, an individual data
meta-analysis would be needed to overcome the limita-
tions of this aggregated data meta-analysis.
CONCLUSIONS
Baseline CRP levels before cardioversion can independ-
ently predict AF recurrence after successful cardiover-
sion. Given the high recurrence rate reported in most
series, the modest positive likelihood ratio for hs-CRP
assays still has high positive predictive value. Future
studies should focus on the evaluation of two or multiple
cut-off points. In the interim, their inclusion in existing
pre-cardioversion evaluation algorithms should be
considered.
Figure 4 Forest plot of the ORs.
Our study indicates that
high-sensitivity C-reactive protein
(hs-CRP) positive patients are
∼5.91 times more likely to
develop a recurrence of atrial
fibrillation than are hs-CRP
negative patients. The estimated
sensitivity and specificity were
relatively consistent across
studies (I2=14.6%).
Figure 3 The receiver operating characteristic (ROC) curve
of high-sensitivity C-reactive protein (hs-CRP). Our analysis
suggests it is highly possible to predict atrial fibrillation using
C-creative protein since the area under the curve generates a
measurement of discrimination ∼0.77. The overall sensitivity
and specificity are relatively high. Five out of nine studies fall
in the 95% CI region, and eight out of nine in the 95%
prediction region.
Yo C-H, Lee S-H, Chang S-S, et al. BMJ Open 2014;4:e004418. doi:10.1136/bmjopen-2013-004418 7
Open Access
Author affiliations
1Department of Emergency Medicine, Far Eastern Memorial Hospital, New
Taipei City, Taiwan
2Department of Rehabilitation and Physical Medicine, Taipei Veteran General
Hospital, Taipei, Taiwan
3Department of Family Medicine, Chang Gung Memorial Hospital, Taoyuan,
Taiwan
4Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang
Gung University, Taoyuan, Taiwan
5Medical Wisdom Consultants, Houston, Texas, USA
6Department of Epidemiology, Harvard School of Public Health, Boston,
Massachusetts, USA
7Department of Emergency Medicine, National Taiwan University Hospital
Yunlin Branch, Douliou, Taiwan
8Department of Emergency Medicine, National Taiwan University Hospital,
Taipei, Taiwan
Contributors C-HY: study design, data management, statistics, first draft, final
draft and approval; S-HL: study design, scientific and statistic advisory, study
monitoring, final draft and approval; S-SC: statistics, final draft and approval;
MC-HL; data collection, final draft and approval; C-CL: design, scientific and
statistic advisory, final draft and approval.
Funding This study was supported by grants of the Far Eastern Memorial
Hospital, Taiwan (FEMH-2013_D_036).
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The study results will be published in a
peer-reviewed scientific journal. The extracted data will open to sharing upon
request.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/3.0/
REFERENCES
1. Fabbri G, Maggioni AP. A review of the epidemiological profile of
patients with atrial fibrillation and heart failure. Expert Rev
Cardiovasc Ther 2012;10:1133–40.
2. Menezes AR, Lavie CJ, DiNicolantonio JJ, et al. Atrial fibrillation in
the 21st century: a current understanding of risk factors and primary
prevention strategies. Mayo Clin Proc 2013;88:394–409.
3. Anderson JL, Halperin JL, Albert NM, et al. Management of patients
with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011
ACCF/AHA/HRS recommendations): a report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol 2013;61:1935–44.
4. Manlucu J, Brancato S, Lane C, et al. Contemporary approaches to
persistent atrial fibrillation. Expert Rev Cardiovasc Ther
2012;10:1421–35.
5. Disertori M, Lombardi F, Barlera S, et al. Clinical characteristics of
patients with asymptomatic recurrences of atrial fibrillation in the
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico-Atrial Fibrillation (GISSI-AF) trial. Am Heart J
2011;162:382–9.
6. Letsas KP, Weber R, Burkle G, et al. Pre-ablative predictors of atrial
fibrillation recurrence following pulmonary vein isolation: the potential
role of inflammation. Europace 2009;11:158–63.
7. Liu T, Li L, Korantzopoulos P, et al. Meta-analysis of association
between C-reactive protein and immediate success of electrical
cardioversion in persistent atrial fibrillation. Am J Cardiol
2008;101:1749–52.
8. Roberts WL, Sedrick R, Moulton L, et al. Evaluation of four
automated high-sensitivity C-reactive protein methods: implications
for clinical and epidemiological applications. Clin Chem
2000;46:461–8.
9. Celebi OO, Celebi S, Canbay A, et al. The effect of sinus rhythm
restoration on high-sensitivity C-reactive protein levels and their
association with long-term atrial fibrillation recurrence after electrical
cardioversion. Cardiology 2011;118:168–74.
10. Barassi A, Pezzilli R, Morselli-Labate AM, et al. Serum amyloid a
and C-reactive protein independently predict the recurrences of atrial
fibrillation after cardioversion in patients with preserved left
ventricular function. Can J Cardiol 2012;28:537–41.
11. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, et al. Relation of
C-reactive protein to the first onset and the recurrence rate in lone
atrial fibrillation. Am J Cardiol 2006;97:659–61.
12. Henningsen KM, Therkelsen SK, Bruunsgaard H, et al. Prognostic
impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation
treated with electrical cardioversion. Scand J Clin Lab Invest
2009;69:425–32.
13. Liu J, Fang PH, Dibs S, et al. High-sensitivity C-reactive protein as a
predictor of atrial fibrillation recurrence after primary circumferential
pulmonary vein isolation. Pacing Clin Electrophysiol 2011;34:398–406.
14. Lombardi F, Tundo F, Belletti S, et al. C-reactive protein but not atrial
dysfunction predicts recurrences of atrial fibrillation after
cardioversion in patients with preserved left ventricular function.
J Cardiovasc Med (Hagerstown) 2008;9:581–8.
15. Loricchio ML, Cianfrocca C, Pasceri V, et al. Relation of C-reactive
protein to long-term risk of recurrence of atrial fibrillation after
electrical cardioversion. Am J Cardiol 2007;99:1421–4.
16. Wazni O, Martin DO, Marrouche NF, et al. C reactive protein
concentration and recurrence of atrial fibrillation after electrical
cardioversion. Heart 2005;91:1303–5.
17. Rizos I, Rigopoulos AG, Kalogeropoulos AS, et al. Hypertension and
paroxysmal atrial fibrillation: a novel predictive role of high sensitivity
C-reactive protein in cardioversion and long-term recurrence. J Hum
Hypertens 2010;24:447–57.
18. Watanabe E, Arakawa T, Uchiyama T, et al. High-sensitivity
C-reactive protein is predictive of successful cardioversion for atrial
fibrillation and maintenance of sinus rhythm after conversion. Int J
Cardiol 2006;108:346–53.
19. Zarauza J, Rodriguez Lera MJ, Farinas Alvarez C, et al.
Relationship between C-reactive protein level and early recurrence
of atrial fibrillation after electrical cardioversion. Rev Esp Cardiol
2006;59:125–9.
20. Leeflang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of
diagnostic test accuracy. Ann Intern Med 2008;149:889–97.
21. Arends LR, Hamza TH, van Houwelingen JC, et al. Bivariate random
effects meta-analysis of ROC curves. Med Decis Making
2008;28:621–38.
22. Harbord RM, Whiting P, Sterne JA, et al. An empirical comparison of
methods for meta-analysis of diagnostic accuracy showed hierarchical
models are necessary. J Clin Epidemiol 2008;61:1095–103.
23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring
inconsistency in meta-analyses. BMJ 2003;327:557–60.
24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997;315:629–34.
25. Buob A, Jung J, Siaplaouras S, et al. Discordant regulation of CRP and
NT-proBNP plasma levels after electrical cardioversion of persistent
atrial fibrillation. Pacing Clin Electrophysiol 2006;29:559–63.
26. Cosgrave J, Foley JB, Bahadur K, et al. Inflammatory markers are
not associated with outcomes following elective external
cardioversion. Int J Cardiol 2006;110:373–7.
27. Ellinor PT, Low A, Patton KK, et al. C-Reactive protein in lone atrial
fibrillation. Am J Cardiol 2006;97:1346–50.
28. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Variation of
inflammatory indexes after electrical cardioversion of persistent atrial
fibrillation. Is there an association with early recurrence rates? Int J
Clin Pract 2005;59:881–5.
29. Psychari SN, Chatzopoulos D, Iliodromitis EK, et al. C-reactive
protein, interleukin 6, and N-terminal pro-brain natriuretic peptide
following cardioversion of atrial fibrillation: is there a role of
biomarkers in arrhythmia recurrence? Angiology 2011;62:310–16.
30. Komatsu T, Sato Y, Ozawa M, et al. Relationship between CHADS2
score and efficacy of antiarrhythmic drug therapy in patients with
paroxysmal atrial fibrillation. Circ J 2013;77:639–45.
31. Letsas KP, Efremidis M, Giannopoulos G, et al. CHADS2 and
CHA2DS2-VASc scores as predictors of left atrial ablation outcomes
for paroxysmal atrial fibrillation. Europace 2014;16:202–7.
32. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive
protein, homocysteine, and plasma lipid levels as predictors of
sudden cardiac death. Circulation 2002;105:2595–9.
33. Parekh RS, Plantinga LC, Kao WH, et al. The association of sudden
cardiac death with inflammation and other traditional risk factors.
Kidney Int 2008;74:1335–42.
34. Streitner F, Kuschyk J, Veltmann C, et al. Role of proinflammatory
markers and NT-proBNP in patients with an implantable cardioverter-
defibrillator and an electrical storm. Cytokine 2009;47:166–72.
35. Korngold EC, Januzzi JL Jr, Gantzer ML, et al. Amino-terminal
pro-B-type natriuretic peptide and high-sensitivity C-reactive protein
8 Yo C-H, Lee S-H, Chang S-S, et al. BMJ Open 2014;4:e004418. doi:10.1136/bmjopen-2013-004418
Open Access
as predictors of sudden cardiac death among women. Circulation
2009;119:2868–76.
36. Engelmann MD, Svendsen JH. Inflammation in the genesis and
perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083–92.
37. Allessie M, Ausma J, Schotten U. Electrical, contractile and
structural remodeling during atrial fibrillation. Cardiovasc Res
2002;54:230–46.
38. Van Wagoner DR. Oxidative stress and inflammation in atrial
fibrillation: role in pathogenesis and potential as a therapeutic target.
J Cardiovasc Pharmacol 2008;52:306–13.
39. Moro C, Hernandez-Madrid A, Matia R. Non-antiarrhythmic drugs
to prevent atrial fibrillation. Am J Cardiovasc Drugs 2010;10:
165–73.
40. den Uijl DW, Delgado V, Tops LF, et al. Natriuretic peptide levels
predict recurrence of atrial fibrillation after radiofrequency catheter
ablation. Am Heart J 2011;161:197–203.
41. Tang Y, Yang H, Qiu J. Relationship between brain natriuretic
peptide and recurrence of atrial fibrillation after successful
electrical cardioversion: a meta-analysis. J Int Med Res 2011;39:
1618–24.
Yo C-H, Lee S-H, Chang S-S, et al. BMJ Open 2014;4:e004418. doi:10.1136/bmjopen-2013-004418 9
Open Access
